Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06838873.5Aexternal-prioritypatent/EP1976877B2/en
Application filed by Abbvie Inc.filedCriticalAbbvie Inc.
Publication of CY1115021T1publicationCriticalpatent/CY1115021T1/en
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Abstract
Η υπό συζήτηση εφεύρεση αφορά σε μονοκλωνικά αντισώματα (π.χ., 8F5 και 8C5) που μπορεί να χρησιμοποιηθούν, για παράδειγμα, στην πρόληψη, θεραπεία και διάγνωση Ασθένειας Alzheimer ή άλλων νευροεκφυλιστικών διαταραχών.The present invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that can be used, for example, in the prevention, treatment and diagnosis of Alzheimer's disease or other neurodegenerative disorders.
CY20141100258T2005-11-302014-04-04
Monoclonal Antibodies Against Amyloid Beta Protein and Their Uses
CY1115021T1
(en)
An antibody that specifically recognizes and binds with a phospho-epitope in the mammalian tau protein or in one of its fragments and a composition comprising the same
IMMUNOGENIC AND CORRESPONDING ANTIBODIES SPECIFIC TO COMMON HIGH MOLECULAR AGGREGATION INTERMEDIATE PRODUCTS OF AMYLOIDS FROM PROTEINS OF DIFFERENT SEQUENCE